NCT07477457 2026-03-17
A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
Clinical Trials
11 trialsNCT00052208 2020-10-30
Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00027625 2018-06-27
Gefitinib Plus Temozolomide in Treating Patients With Malignant Primary Glioma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT00025675 2018-06-26
Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT01310855 2017-05-31
Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma
University College, London
Phase 2 Terminated
NCT00085566 2016-01-20
Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00042991 2014-05-28
Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00014170 2013-07-16
Gefitinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2 Completed
NCT00016991 2013-06-20
ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse
Duke University
Phase 2 Completed
NCT00052754 2012-09-24
Gefitinib in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00132158 2012-04-17
ZD1839 and Oral Irinotecan in Treating Young Patients With Refractory Solid Tumors
St. Jude Children's Research Hospital
Phase 1 Completed